Table 4.
Evaluation of the effect of laboratory characteristics on the treatment outcome of cancer patients with COVID-19 using logistic regression model
| Variable | Category | OR(95% CI) |
|---|---|---|
| Hemoglobin (g/dl) | < 12 | 1 |
| 12–16 | 0.55 (0.16–1.91) | |
| > 16 | 2.33 (0.31–17.54) | |
| Lymphocyte (μl) | < 20 | 1 |
| 20–40 | 0.84 (0.11–1.67) | |
| > 40 | 1.67 (0.14–20.31) | |
| NA | < 135 | 1 |
| 135–145 | 0.64 (0.21–1.96) | |
| K | 3.5–5 | 1 |
| < 3.5 | 1.07 (0.17–6.91) | |
| Partial thromboplastin time (PTT) | < = 45 | 1 |
| > 45 | 1.68 (0.31–9.22) | |
| Erythrocyte sedimentation rate (ESR) (female < 10 and male < 20) | Yes | 1 |
| No | 1.61 (0.57–4.58) | |
| Creatinine (mg/dl) | < = 1.2 | 1 |
| > 1.2 | 1.67 (0.55–5.13) | |
| Blood Urea Nitrogen (BUN) | < 10 | 1 |
| 10–43 | 1.39 (0.25–7.91) | |
| > 43 | 5.0 (0.47–52.96) | |
| Aspartate Aminotransferase (AST) | < = 40 | 1 |
| > 40 | 1.91 (0.68–5.51) | |
| Alanine Aminotransferase (ALT) | < = 40 | 1 |
| > 40 | 1.68 (0.56–4.97) | |
| Alkaline Phosphatase (ALK-p) (IU/L) | < = 200 | 1 |
| > 200 | 1.20 (0.41–3.54) | |
| Platelets | < 150 | 1 |
| > = 150 | 1.16 (0.37–3.66) | |
| Hematocrit | < 36 | 1 |
| 36–48 | 0.48 (0.12–1.92) | |
| > 48 | 1.67 (0.11–5.87) | |
| Lactate dehydrogenase (LDH) | 313–618 | 1 |
| < 313 or > 618 | 2.89 (1.19–8.1)* | |
| White blood cell (WBC) | < 4000 | 1 |
| 4000–12,000 | 2.93 (0.31–28.2) | |
| > 12,000 | 2.14 (0.12–16.9) | |
| Temperature( o c) | < = 37 | 1 |
| > 37 | 2.61 (0.85–7.90) |
*Statistically significant